Ogino Shuji, Nishihara Reiko, VanderWeele Tyler J, Wang Molin, Nishi Akihiro, Lochhead Paul, Qian Zhi Rong, Zhang Xuehong, Wu Kana, Nan Hongmei, Yoshida Kazuki, Milner Danny A, Chan Andrew T, Field Alison E, Camargo Carlos A, Williams Michelle A, Giovannucci Edward L
From the aDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; bDivision of MPE Molecular Pathological Epidemiology, Brigham and Women's Hospital, Boston, MA; cDepartment of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; dDepartment of Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA; eDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA; fDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA; gYale Institute for Network Science, Yale University, New Haven, CT; hInstitute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom; iDivision of Gastroenterology, Massachusetts General Hospital, Boston, MA; jChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; kDepartment of Epidemiology, Richard M. Fairbanks School of Public Health, Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; lDivision of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; mDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA; nDivision of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, MA; and oDepartment of Emergency Medicine, Massachusetts General Hospital, Boston, MA.
Epidemiology. 2016 Jul;27(4):602-11. doi: 10.1097/EDE.0000000000000471.
Molecular pathology diagnostics to subclassify diseases based on pathogenesis are increasingly common in clinical translational medicine. Molecular pathological epidemiology (MPE) is an integrative transdisciplinary science based on the unique disease principle and the disease continuum theory. While it has been most commonly applied to research on breast, lung, and colorectal cancers, MPE can investigate etiologic heterogeneity in non-neoplastic diseases, such as cardiovascular diseases, obesity, diabetes mellitus, drug toxicity, and immunity-related and infectious diseases. This science can enhance causal inference by linking putative etiologic factors to specific molecular biomarkers as outcomes. Technological advances increasingly enable analyses of various -omics, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, metagenomics, microbiome, immunomics, interactomics, etc. Challenges in MPE include sample size limitations (depending on availability of biospecimens or biomedical/radiological imaging), need for rigorous validation of molecular assays and study findings, and paucities of interdisciplinary experts, education programs, international forums, and standardized guidelines. To address these challenges, there are ongoing efforts such as multidisciplinary consortium pooling projects, the International Molecular Pathological Epidemiology Meeting Series, and the Strengthening the Reporting of Observational Studies in Epidemiology-MPE guideline project. Efforts should be made to build biorepository and biobank networks, and worldwide population-based MPE databases. These activities match with the purposes of the Big Data to Knowledge (BD2K), Genetic Associations and Mechanisms in Oncology (GAME-ON), and Precision Medicine Initiatives of the United States National Institute of Health. Given advances in biotechnology, bioinformatics, and computational/systems biology, there are wide open opportunities in MPE to contribute to public health.
在临床转化医学中,基于发病机制对疾病进行亚分类的分子病理学诊断越来越普遍。分子病理流行病学(MPE)是一门基于独特疾病原理和疾病连续体理论的综合性跨学科科学。虽然它最常用于乳腺癌、肺癌和结直肠癌的研究,但MPE可以研究非肿瘤性疾病的病因异质性,如心血管疾病、肥胖症、糖尿病、药物毒性以及免疫相关和感染性疾病。这门科学可以通过将假定的病因因素与作为结果的特定分子生物标志物联系起来,增强因果推断。技术进步越来越能够对各种组学进行分析,包括基因组学、表观基因组学、转录组学、蛋白质组学、代谢组学、宏基因组学、微生物组学、免疫组学、相互作用组学等。MPE面临的挑战包括样本量限制(取决于生物样本或生物医学/放射成像的可用性)、对分子检测和研究结果进行严格验证的需求,以及跨学科专家、教育项目、国际论坛和标准化指南的匮乏。为应对这些挑战,正在开展多学科联盟汇总项目、国际分子病理流行病学会议系列以及加强流行病学观察性研究报告-MPE指南项目等工作。应努力建立生物样本库和生物银行网络,以及全球基于人群的MPE数据库。这些活动符合美国国立卫生研究院的大数据到知识(BD2K)、肿瘤学中的基因关联和机制(GAME-ON)以及精准医学计划的目标。鉴于生物技术、生物信息学以及计算/系统生物学的进展,MPE在促进公共卫生方面有广阔的机会。